Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases.

Liu, Drolaiz H W; Grabsch, Heike I; Gloor, Beat; Langer, Rupert; Dislich, Bastian (2023). Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases. Journal of cancer research and clinical oncology, 149(14), pp. 13345-13352. Springer 10.1007/s00432-023-05142-x

[img]
Preview
Text
s00432-023-05142-x.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (652kB) | Preview

BACKGROUND

Combination of immunotherapy and chemotherapy is recommended for first line treatment of gastric adenocarcinoma (GC) patients with locally advanced unresectable disease or metastatic disease. However, data regarding the concordance rate between PD-L1 combined positive score (CPS) in primary GC and matched regional lymph node metastasis (LNmet) or matched distant metastasis (Dmet) is limited.

METHODS

Tissue microarray sections from primary resected GC, LNmet and Dmet were immunohistochemically stained with anti-PD-L1 (clone SP263). PD-L1 expression was scored separately in tumour cells and immune cells and compared between matched primary GC, LNmet and/or Dmet. CPS was calculated and results for CPS cut-offs 1 and 5 were compared between matched samples.

RESULTS

275 PD-L1 stained GC were analysed. 189 primary GC had matched LNmet. CPS cut-off 1 concordance rate between primary GC and LNmet was 77%. 23 primary GC had matched Dmet but no matched LNmet, CPS cut-off 1 concordance rate was 70%. 63 primary GC had both matched LNmet and matched Dmet, CPS cut-off 1 concordance rate of 67%. CPS cut-off 5 results were similar. The proportion of PD-L1 positive tumour cells increased from primary GC (26%) to LNmet (42%) and was highest in Dmet (75%).

CONCLUSION

Our study showed up to 33% discordance of PD-L1 CPS between primary GC and LNmet and/or Dmet suggesting that multiple biopsies of primary GC and metastatic sites might need to be tested before considering treatment options. Moreover, this is the first study that seems to suggest that tumour cells acquire PD-L1 expression during disease progression.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Visceral Surgery

UniBE Contributor:

Gloor, Beat, Dislich, Bastian

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

1432-1335

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

27 Jul 2023 13:38

Last Modified:

20 Oct 2023 00:13

Publisher DOI:

10.1007/s00432-023-05142-x

PubMed ID:

37491637

Uncontrolled Keywords:

Gastric cancer Heterogeneity Immunohistochemistry Metastases PD-L1

BORIS DOI:

10.48350/185073

URI:

https://boris.unibe.ch/id/eprint/185073

Actions (login required)

Edit item Edit item
Provide Feedback